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Abstract 
Myostatin regulates skeletal muscle size via the activin receptor IIB (ActRIIB). However, its 
effect on muscle energy metabolism and energy dependent muscle function remains largely 
unexplored. This question needs to be solved urgently since various therapies for neuromus-
cular diseases based on blockade of ActRIIB signaling are being developed. Here we show in 
mice that four months of pharmacological abrogation of ActRIIB signaling by treatment with 
soluble ActRIIB-Fc triggers extreme muscle fatigability. This is associated with elevated se-
rum lactate levels and a severe metabolic myopathy in the mdx mouse, an animal model of 
Duchenne muscular dystrophy. Blockade of ActRIIB signaling down-regulates Porin, a cru-
cial ADP/ATP shuttle between cytosol and mitochondrial matrix leading to a consecutive 
deficiency of oxidative phosphorylation as measured by in vivo Phophorus Magnetic Reson-
ance Spectroscopy (31P-MRS). Further, ActRIIB blockade reduces muscle capillarization, 
which further compounds the metabolic stress. We show that ActRIIB regulates key determi-
nants of muscle metabolism, such as Pparβ, Pgc1α, and Pdk4 thereby optimizing different 
components of muscle energy metabolism. In conclusion, ActRIIB signaling endows skeletal 
muscle with high oxidative capacity and low fatigability. The severe metabolic side effects 
following ActRIIB blockade caution against deploying this strategy, at least in isolation, for 
treatment of neuromuscular disorders. 
Key words: ActRIIB, myostatin, metabolic myopathy, muscle fatigue, oxidative phosphory-
lation, beta-oxidation, Duchenne muscular dystrophy, mdx mouse. 
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INTRODUCTION 
Skeletal muscle has inbuilt control mechanisms to prevent overgrowth. This function is ex-
ecuted, at least in part, by secreted molecules including members of the transforming growth 
factor-β (TGF-β) family, especially myostatin1. Myostatin signals via its transmembrane acti-
vin receptor IIB (ActRIIB) and suppression of this pathway stimulates muscle growth2,3. In 
the past few years, strategies have been developed to treat muscular dystrophies, muscle wast-
ing and cachexia by blocking the myostatin/ActRIIB pathway with first of many clinical trials 
already being concluded (ClinicalTrials.gov NCT01099761, NCT01519349, NCT01423110, 
NCT01669174, NCT01601600, NCT01433263). However, it remains a matter of controversy 
whether the hypertrophic muscles that form as a result of blocking myostatin/ActRIIB signal-
ing confer any functional benefit, because a number of groups have reported loss of specific 
force of larger muscles in myostatin knockout mice and a faster fatigability (Mstn-/-)4-6. In 
addition, myostatin knockout leads to a change of muscle contractile and metabolic characte-
ristics towards a “glycolytic” phenotype5,7,8, commonly attributed to a change in muscle speci-
fication during development. In contrast to the constitutive myostatin deficiency of Mstn-/- 
mice, postnatal treatment with soluble activin IIB receptor (sActRIIB-Fc) in adult mice blocks 
myostatin/ActRIIB signaling and increases muscle force without altering the fiber type com-
position9,10. Similar results have been obtained in the mdx mouse model of Duchenne muscu-
lar dystrophy11,12. However, a recent transcriptome profiling demonstrated a down-regulation 
of genes involved in oxidative phosphorylation and mitochondrial function following treat-
ment with sActRIIB-Fc.13 Another study revealed a faster decline of muscle force following 
repetitive stimulation14. Whether those changes reflect solely a change towards a faster mus-
cle phenotype or a relevant mitochondrial dysfunction is presently unknown. In the view of 
ongoing clinical trials we need to address the question of how myostatin blockade affects the 
metabolism of dystrophic muscle in mdx mice, which already has a preexisting deficit of mi-
tochondrial function15-17. Here we explored the hypothesis that ActRIIB signaling is a key 
regulator of oxidative metabolism in the adult muscle. We thus set out to systematically inves-
tigate in adult wild-type and mdx mice, how postnatal blockade of ActRIIB signaling using 
sActRIIB-Fc might affect muscle energy metabolism and energy dependent muscle function. 
Our data conclusively show the importance of ActRIIB signaling as a pivotal link that acts to 
balance muscle size and strength against endurance capacity via optimization of energy meta-
bolism. 
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RESULTS 
ActRIIB blockade in adult wild-type mice increases fatigability. Muscles of Mstn-/- mice, a 
model of constitutive inhibition of signaling via ActRIIB, exhibit a congenital fiber-type pro-
file that is characterized by an increase in the number of fast “glycolytic” (MHCIIB) fibers 
and concomitant loss of “oxidative” (MHCI, MHCIIA) fibers, which entails changes in mus-
cle function, exercise capacity and muscle metabolism4,7,8,18,19. To circumvent the effects of 
congenital fiber-type switching, we here inhibited ActRIIB signaling in adult wild-type mice 
with a soluble form of the activin receptor fused with the Fc-fragment of mouse IgG (sAc-
tRIIB-Fc). Four months of treatment promoted robust skeletal muscle growth together with a 
significant increase in total body weight, confirming previously published data (Fig. S1)20. 
Importantly, the increase in muscle mass was not accompanied by fiber-type conversion (Fig. 
S2). The absolute maximal force of EDL and soleus muscle increased in parallel with muscle 
size (Figs. 1a,c). Specific maximal force was conserved, implicating a proportional increase 
of force and muscle mass (Fig. 1b). However, sActRIIB-Fc treatment also increased muscle 
fatigue (Figs. 1c,d) and mice exhausted precociously during incremental speed running tests 
(Figs. 1e,g). Serum lactate, being already significantly increased at resting state, rose to pa-
thological levels following incremental speed running (Figs. 1f,g). The concept of “Critical 
Speed” accurately reflects the capacity for aerobic exercise and is based on the proportional 
relationship between “covered distance” and “time to exhaustion” at different velocities21. 
During the four months treatment period, we found a steady decline in Critical Speed in the 
treatment and control group, however, the decline over time was by far larger in sActRIIB-Fc 
treated animals as compared to PBS-treated mice (Figs. 1h,i). 
Severe exercise intolerance in dystrophic mdx mice following treatment with sActRIIB-Fc. 
In Duchenne muscular dystrophy and its mdx mouse model, oxidative metabolism is com-
promised due to membrane damage and the resulting intracellular calcium overload15-17. Hav-
ing shown that ActRIIB blockade decreased aerobic exercise capacity in wild-type mice, we 
now investigated what effect administration of sActRIIB-Fc would have on the metabolic 
phenotype of mdx mice. This information would have important clinical implications for the 
strategies to use ActRIIB blockade for treatment of muscular dystrophies. Despite a massive 
increase in skeletal muscle mass after sActRIIB-Fc treatment (Fig. S1), absolute maximal 
force decreased in soleus muscle and most notably specific force in both EDL and soleus 
muscles (Figs. 2a,b), serving as functional evidence for increased myopathic changes of sAc-
tRIIB-treated dystrophic mdx muscle. Interestingly, sActRIIB-Fc treatment did not cause any 
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greater force decline during repetitive stimulation (Figs. 2c,d). Electromyography excluded 
problems in neuromuscular transmission but revealed abnormal spontaneous potentials and 
the presence of complex repetitive discharges in both PBS and sActRIIB-Fc treatment groups 
of the mdx mice (Fig. S3). Such polyphasic potentials are characteristic of dystrophic mdx 
muscle22. As voluntary motor activity seemed reduced when observing sActRIIB-Fc treated 
mdx mice, we proceeded to analyze their exercise behavior. Remarkably, at the end of the 
treatment period, sActRIIB-Fc treated mdx mice suffered from severe exercise intolerance 
associated with a pathological serum lactate increase (Figs. 2e-g, Supplemental Video). It is 
important to note, that exercise capacity of mdx mice declined throughout the four months 
treatment period, however, to a far larger extent in sActRIIB-Fc treated mdx mice than in the 
PBS-treated control group (Figs. 2h,i). 
sActRIIB-Fc treatment affects muscle capillarization. The ability of mitochondria to pro-
duce ATP critically depends on the oxygen supply via tissue blood perfusion, thus a combina-
tion of hypoperfusion plus exercise induced hypoxemia might explain the severe exercise 
intolerance. Treatment with sActRIIB-Fc caused a drop in capillary density especially in the 
oxidative soleus muscle from mdx mice with a subsequent increase in the capillary domain 
(Figs. 3a-d). The increase of the capillary domain was also found in glycolytic EDL muscles 
of mdx mice, albeit to a lesser degree (Fig. S4a-d). Treatment of mice as well as of C2C12 
myotubes with sActRIIB-Fc down-regulated expression of Vegf-A suggesting an indirect neg-
ative effect of myostatin blockade on capillary formation (Figs. 3e,f). Interestingly, Vegf-A 
expression in mdx mice was much lower than in wild-type mice, and treatment with sAc-
tRIIB-Fc did not decrease Vegf-A mRNA-abundance any further (Fig. 3e), suggesting the 
presence of additional mechanisms for regulating capillary density. In this regard the findings 
of Hayot et al. (2010) are of special interest, who reported an induction of myostatin expres-
sion in muscles of rats exposed to chronic hypoxia and in patients with chronic obstructive 
pulmonary disease (COPD). The authors interpreted these findings as a potential cause for the 
muscle wasting that is often seen in COPD-patients23. These findings, however, could also be 
interpreted as a compensatory up-regulation of myostatin to improve the metabolic function-
ing and to increase capillary density in a state of chronic hypoxia. It is of special interest that 
endothelial cells strongly express the mRNAs of transmembrane receptors (ActRIIA/B and 
ALK4/5) for myostatin or its homologs, whereas myostatin mRNA was only expressed at low 
levels (Fig. 3g). Treatment of endothelial cells (HUVEC cell line) with increasing dosages of 
recombinant myostatin in vitro increased the cell doubling time in culture, verifying a direct 
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effect of myostatin or its homologs on endothelial cell proliferation (Fig. S4e), however, the 
exact ligands of muscle endothelial cell regulation in vivo remain to be determined. 
ActRIIB signaling regulates Pgc1α and Ppar transcription factors. The exercise intolerance 
and lactic acidosis following ActRIIB blockade suggests underlying changes in muscle meta-
bolism, a hypothesis supported by previous transcriptome profiling13. In agreement, we show 
that the copy numbers of Pgc1α and Pparβ, which are key transcription factors promoting 
oxidative metabolism in skeletal muscle, are down-regulated after treatment with sActRIIB-
Fc (Figs. 4b,c) and following treatment of C2C12 myotubes with sActRIIB-Fc (Fig. 4g). On 
the protein level, down-regulation of Pgc1α was more pronounced in the mdx muscle if re-
ferred to desmin abundance (Fig. 4a). Such loss of oxidative properties was accompanied by a 
compensatory activity increase of enolase, a key glycolytic enzyme (Fig. 4d). Furthermore, 
mRNA levels of Pdk4, an inhibitor of pyruvate dehydrogenase (Pdh) and a regulatory switch 
of substrate utilization from glucose towards fatty acids24, was strongly decreased following 
sActRIIB-Fc treatment in mdx mice (Fig. 4e). We thus expected an inhibitory effect of sAc-
vRIIB-Fc treatment on β-oxidation and found a down-regulation of Cpt1b mRNA levels (Fig. 
4f). Likewise, sActRIIB-Fc treatment of C2C12 myotubes reduced expression of genes control-
ling oxidative metabolism and β-oxidation within 24 hours of treatment (Fig. 4g), implying a 
direct effect of myostatin signaling in the regulation of these genes. 
We further focused our attention on the neuronal nitric oxide synthase (Nos1, nNos), because 
it is well known that the sarcolemmal presence of the Nos1 enzyme is strongly reduced in the 
absence of its binding partner dystrophin in patients with DMD and in mdx mice25,26. The re-
sulting dysregulation of NO-synthesis entails a failure of contraction induced vasodilatation as 
well as changes in the cellular calcium homeostasis associated with exacerbated post-exercise 
fatigability, exercise-induced muscle edema and cell necrosis27,28. We thus wondered, whether 
sActRIIB-Fc treatment would influence sarcolemmal Nos1 expression, hence further com-
promising the pathophysiological effect of sActRIIB-Fc on vasculature and oxidative meta-
bolism. As expected, we found a strong decrease of Nos1 mRNA copy numbers in mdx mus-
cles of both treatment groups in comparison to wild-type muscle (Fig. S11a), which was par-
alleled by a strong decrease of sarcolemmal expression of Nos1 protein in mdx muscle (Fig. 
S11b). Furthermore, treatment with sActRIIB-Fc diminished Nos1 transcription in wild-type 
and mdx muscle (Fig. S11a). However, subsarcolemmal Nos1 protein content remained un-
changed (Fig. S11b), and Western blot did not reveal any changes in Nos1 protein levels in 
wild-type mice (Fig. S11c), whereas Nos1 protein levels in mdx mice were below detection 
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levels (data not shown). This suggests that sActRIIB-Fc treatment unlikely aggravates NO 
dysregulation of dystrophin deficient muscle, although further experiments are required to 
ascertain or to exclude a role of the ActRIIB-receptor on NO signaling. 
Reduced oxidative metabolism in mdx muscle following treatment with sActRIIB-Fc. It 
should be noted that the mRNA and protein levels of key regulatory genes (Pparβ, Pgc1α) 
important for oxidative metabolism (Figs. 4a-c) were significantly lower in mdx than in wild-
type mice, supporting previous findings that oxidative muscle metabolism is depressed in dy-
strophic muscle to some extent15,29. 
We therefore studied in real-time the response of the oxidative metabolism to a standardized 
bout of exercise in anesthetized mdx mice either treated with PBS (controls) or sActRIIB-Fc. 
Muscle function and energy metabolism were assessed strictly noninvasively in calf muscle 
with an innovative experimental setup using phosphorus (31P) nuclear magnetic resonance 
spectroscopy (MRS)30. An exercise bout of six minutes consisting of repeated maximal iso-
metric contractions was induced in vivo by transcutaneous electro-stimulation. After induced 
repeated contractions fatigue levels (Fig. 5a), intracellular acidosis (Fig. 5b) as well as pho-
sophocreatine (PCr) consumption (Fig. 5c) were similar in both groups. However, the time 
constant of post-exercise phosphocreatine re-synthesis (τPCr) was significantly prolonged in 
sActRIIB-Fc treated mdx mice (Figs. 5d,e). Given that PCr synthesis during the post-exercise 
recovery period relies exclusively on oxidative ATP synthesis, τPCr has largely been ac-
knowledged as an important in vivo index of oxidative mitochondrial capacity. Hence the pro-
longed τPCr demonstrates that sActRIIB-Fc treatment reduces oxidative metabolism in vivo. 
The MRS results pointed to an underlying functional deficit of the skeletal muscle respiratory 
chain complexes or β-oxidation in response to sActRIIB-Fc treatment. However, contrary to 
our hypothesis, we found (i) largely unaffected ex vivo activities of isolated key mitochondrial 
enzymes (Krebs cycle: citrate synthase [CS]; respiratory chain: cytochrome C oxidase [COX]; 
and β-oxidation: hydroxyacyl-CoA-dehydrogenase [HADHA]) and (ii) similar succinate de-
hydrogenase [SDH] and COX fiber profiles (Figs. S5-S7). In fact, COX and SDH enzyme 
activities even appeared somewhat increased in EDL muscles (Figs. S5c,d, S6a, S7a), likely 
reflecting a compensatory increase in response to decreased aerobic energy production. Fur-
thermore, mitochondrial DNA (mtDNA) copy numbers remained largely unchanged follow-
ing treatment with sActRIIB-Fc (Fig. S8a). The normal mtDNA copy numbers together with 
unaltered CS enzyme activities (Fig. S5a,b) let us conclude that ActRIIB blockade did not 
affect mitochondrial mass. 
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Treatment with sActRIIB-Fc down-regulates porin expression in wild-type and mdx mus-
cle. Given the abnormal post-exercise PCr re-synthesis (τPCr) along with normal respiratory 
chain activities, we wondered whether the ATP transport from the mitochondrial matrix into 
the cytosol of skeletal muscle cells might be affected, which might explain the diminished rate 
of aerobic energy production. Keeping with such hypothesis, decreased protein levels of 
Vdac3 had already been reported for mdx muscle, hinting towards a derangement of the 
ADP/ATP-shuttling system through the outer mitochondrial membrane via the Voltage De-
pendent Anion Channels (Vdac, syn. porin)31,32,33. In line with these findings, a proteomic 
survey of differentially expressed proteins from wild-type and mdx mouse hearts had discov-
ered a substantial loss of Vdac1 protein34. Indeed, here we show that wild-type and to an even 
larger extent mdx muscles exhibited a considerable reduction of Porin mRNA-transcripts 
(Fig. S8a) and porin protein levels (Fig. S9) after sActRIIB-Fc treatment. This pushes the 
muscle even further into global mitochondrial dysfunction than dystrophin deficiency alone. 
Such secondary mitochondriopathy might explain the high lactic acidosis and rapid fatigabili-
ty of sActRIIB-Fc treated mdx mice. 
Myopathic changes in mdx mice following treatment with sActRIIB-Fc. We next investi-
gated the consequences of sActRIIB-Fc treatment on the extent of muscle dystrophy in mdx 
mice. Muscles from both sActRIIB-Fc and PBS-treatment groups revealed typical dystrophic 
changes comprising muscle fiber necrosis, regenerating fibers, fibers with central nuclei, in-
flammatory infiltrates, and increased fibrosis, which are difficult to quantify (Fig. S10a). 
Muscle degeneration is accompanied by a leak of cytoplasmic enzymes such as creatine ki-
nase (CK). We measured serum CK levels, which were largely elevated in mdx mice from 
both treatment groups; however, we did not detect any significant differences since inter-
individual variation was large (Fig. S10b). In mdx mice, muscle degeneration is followed by 
excessive regeneration with abundant splitting of regenerated fibers, which appear as small 
fiber profiles on transverse sections. Such excessive regeneration leads to an increase of mus-
cle mass (see comparison between wild-type and mdx mice: Fig. S1). Following treatment 
with sActRIIB-Fc, muscles enlarged on average, if compared to PBS treatment, by ≈1.6 fold 
in mdx and by ≈1.3 fold in wild-type mice (Fig. S1). However, analysis of morphometric fea-
tures of EDL muscles from sActRIIB-Fc treated mdx mice, revealed a further increase in the 
number of small fiber profiles if compared to PBS-treated mdx mice (Fig. S10c). This finding 
suggestes that the excessive increase of muscle weight was triggered by abnormal regenera-
tion and not by fiber hypertrophy. The soleus muscle of mdx mice, while not increasing its 
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mass after sActRIIB-Fc treatment, exhibited an increased fiber size variation (Fig. S10d). In 
conclusion, the dystrophic phenotype of dystrophin deficient muscle persisted or even in-
creased following treatment with sActRIIB-Fc. 
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DISCUSSION 
Myostatin/ActRIIB signaling exerts three major functions on skeletal muscle. (i) It acts to 
limit its size, (ii) promotes oxidative properties, and (iii) balances glucose versus fat utiliza-
tion. The changes in muscle physiology in hypermuscular mice following treatment of adult 
mice with sActRIIB-Fc highlights the fact that myostatin/ActRIIB blockade confers little 
functional advantage over wild-type muscle due to its rapid fatigability. Improved muscle 
strength, however short lived, comes at the cost of increased fatigability and exercise intoler-
ance, which is often seen in patients with mitochondrial disorders such as MELAS or MERRF 
syndrome35. Interestingly, muscle cramps are frequently observed in whippet dogs with ho-
mozygous Mstn mutations36. Moreover, “double muscle cattle”, several breeds of which have 
been identified to carry Mstn mutations37,38, are prone to exercise induced lactic acidosis and 
severe rhabdomyolysis39,40. In myostatin deficient animals, such exercise failure could be at-
tributed to congenital fiber-type disproportion with a shift towards the expression of the fast 
IIB myosin heavy chain (MHC) isoform4,18, which is well known to be associated with loss of 
oxidative properties of skeletal muscle and increased fatigability5,8. In contrast to animals 
born with mutations in the Mstn gene, we show that blockade of ActRIIB signaling in adult 
wild-type mice beyond the period of muscle development does not have any impact on fiber-
type composition, thus confirming previous reports10. 
After sActRIIB-Fc treatment, the mice exhibit clinical signs of early muscle fatigue, exercise 
intolerance, and lactic acidosis – characteristic signs for a depression of β-oxidation, a shift 
towards anaerobic glycolysis, and ATP-deficiency. Interestingly, whereas ex vivo mitochon-
drial respiratory chain enzyme activities and mtDNA copy numbers were within the normal 
range, in vivo 31P-MRS clearly demonstrated a down-regulation of oxidative energy metabol-
ism in sActRIIB-Fc treated mdx mice. We further demonstrate a significant loss of the Porin 
complex in sActRIIB-Fc treated mice, pointing towards an underlying defect of ATP-
handling and ATP-transport as one causative mechanism for the metabolic phenotype. A 
second aggravating factor, which further compromised exercise tolerance, is the decrease of 
capillary density and the increase of the capillary domain. Previous reports attributed such 
reduced capillary density to the increase of muscle fiber size41. However, here we demonstrate 
a net numerical loss of capillaries per fiber following treatment with sActRIIB-Fc. This find-
ing was most pronounced in mdx mice with a profound rarefication of the capillary bed in 
dystrophic muscle. In dystrophinopathies diminished sarcolemmal Nos1 results in dysregula-
tion of the capillary adaptive response to exercise leading to functional muscle ischemia42. 
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Our protein analysis argues against a further aggravation of the capillary adaptive response by 
additional loss of Nos1 in sActRIIB-Fc treated animals, despite the fact that Nos1 mRNA le-
vels were clearly reduced. sActRIIB-Fc treatment of dystrophic mdx mice dramatically wor-
sened the myopathic phenotype as shown by the large deficit in specific force. As lack of dy-
strophin per se alters mitochondrial function in DMD patients and mdx mice15,16,29, the block-
ade of myostatin signaling initiates a vicious cycle resulting in severe secondary metabolic 
myopathy. We also found an increased fiber size variation after sActRIIB-Fc treatment of 
mdx mice pointing towards increased myopathic changes even at the tissue level. 
In the past, several investigators have used different strategies of interfering with the ActRIIB 
receptor mediated signaling pathway in order to treat mdx mice and GRMD dogs. This was 
done either through injection of sActRIIB-Fc12,43, AAV-mediated gene transfer11 or antibodies 
directed against the ActRIIB receptor44. Overall, the conclusions were optimistic about the 
usefulness of such strategy to treat dystrophinopathies. However, it should be noted that our 
results and conclusions differ from previously published work in various aspects. We think 
the reason for that mainly lies in the choice of endpoints to define success or failure of such a 
treatment. For DMD patients, clinically relevant and quantifiable improvements would com-
prise better performance in the six-minutes walk45 and improvement of respiratory function. 
This implies the ability of the patient’s body to maintain a certain workload for a prolonged 
time period and not just to be able to produce single bouts of maximum short-duration muscle 
activity as tested by tetanic muscle contractions11,12 or by the whole body tension method43. In 
most studies, the increase of muscle size was taken as an endpoint11,44, automatically assum-
ing that big muscles are healthier muscles. This basic assumption is put into question by our 
results. None of the studies investigated endurance capacity, which evaluates the effect of a 
treatment on the physiology of the entire body over a longer time period and would thus be a 
relevant parameter that could translate into improvement of life quality in patients. Several 
studies, one using the identical sActRIIB-Fc compound12, reported a small, but significant 
decline of CK values after ActRIIB blockade11,12. We were unable to reproduce this finding, 
the reason for these differences remaining unresolved. 
We show that myostatin controls the metabolic profile of skeletal muscle, and its blockade 
depresses the main molecular determinants of oxidative metabolism and β-oxidation. Interes-
tingly, genetic inactivation of Pparβ, similar to myostatin/ActRIIB blockade, reduced oxida-
tive properties of skeletal muscle46. This adds further evidence that myostatin controls the 
muscle oxidative phenotype via peroxisome proliferator-activated receptors (PPAR) and 
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Pgc1α, the downstream target of Pparβ, while the down-regulation of Pdk4 indicates a shift 
away from β-oxidation towards glucose metabolism. These qPCR data are strongly corrobo-
rated by a recent transcriptome study following treatment with sActRIIB-Fc of wild-type 
mice13. However, we lack direct evidence to ascertain a shift towards higher glucose metabol-
ism, although the down-regulation of Pdk4 and up-regulation of Enolase can be counted as 
indirect indicators for such a change. The unfavorable combination of decreased vasculariza-
tion and metabolic changes after ActRIIB blockade is likely to cause a rapid imbalance be-
tween increased cytosolic ATP hydrolysis and insufficient mitochondrial ATP synthesis dur-
ing exhaustive exercise. The subsequent shift towards anaerobic glycolytic ATP synthesis 
explains the rapid fatigability and the pathologically increased lactate production47. However, 
the metabolic adaption in response to myostatin may differ in diverse physiological and pa-
thophysiological contexts, e.g. myostatin inhibition was reported to improve motor perfor-
mance in aged mice48. Further work is required to elucidate the metabolic function of myosta-
tin in different disease situations and during ageing.  
In conclusion, our results suggest that myostatin/ActRIIB signaling optimizes oxidative meta-
bolism of skeletal muscle leading to lower muscle fatigability and amelioration of endurance 
capacity. Such fundamental functions of myostatin should be taken into account in the devel-
opment of therapies based on myostatin/ActRIIB blockade. However, it should be kept in 
mind that our experimental design does not allow to determine which effects can be ascribed 
to myostatin blockade alone and which to the inactivation of other TGF-β family members 
such as bone morphogenetic proteins (BMP), growth and differentiation factors (GDF) and 
activins that may also be sequestered by the soluble ActRIIB. Further investigations are re-
quired to answer the question, such as whether emerging therapies based on PPAR agonists 
might be able to prevent such adverse effects of ActRIIB blockade on the oxidative metabol-
ism and on exercise tolerance. Furthermore, dose regime studies could answer the question, 
whether short-term treatment or pulse treatment may circumvent secondary effects of myosta-
tin/ActRIIB blockade on muscle metabolism. 
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MATERIALS AND METHODS 
Animals. Male mdx mice (on a C57BL/10ScSn background) were bred in the animal facility 
of the Medical Faculty of Paris VI and kept according to institutional guidelines. Wild-type 
male C57BL/6J control mice were purchased from Charles River (France). Two-months-old 
wild-type and mdx mice were injected twice weekly subcutaneously with 10 mg/kg with the 
rodent form of the soluble activin receptor IIB (sActRIIB-Fc; Acceleron Pharma) for a total of 
four months before sacrifice. The methods of sActRIIB-Fc synthesis have previously been 
described49. All animal studies have been approved and were carried out under the laboratory 
and animal facility licenses A75-13-11 and A91-228-107. 
Evaluation of the critical speed. Mice were subjected to three or four separate bouts of runs 
until exhaustion at various treadmill speeds (between 20 and 80 cm/s according to individual 
motor capacity, one run per day) according to previously published protocols21. Critical 
Speed, an index of the aerobic exercise capacity, was calculated from the slope (a) of the re-
gression line, plotting the distance (y) against the time to exhaustion (x) from the different 
runs. 
Blood lactate assessment during exhaustive exercise. Lactate concentrations were deter-
mined in blood samples collected from the tip of the tail using a Lactate pro LT device (Ar-
kray Inc, Kyoto, Japan) at rest before exercise (0 min) and 5 min after treadmill running-
induced exhaustion. Exhaustion was defined as the time point at which the mice were unable 
to run anymore and stayed on the grid despite repeated electric stimulation. The running test 
started at the lowest speed of 5 cm/s to allow a warm-up and then increased by 1 cm/s every 
30 seconds until exhaustion. This protocol is illustrated by the Supplemental Video, which 
demonstrates the running test of sActRIIB-Fc treated wild-type (left) and mdx mice (right) 
side by side. The starting speed of 5 cm/s was increased by 1 cm/s every minute until exhaus-
tion of the mdx mouse at 19 cm/s after 14 minutes, while the wild-type mouse was still able to 
run at a speed of 40 cm/s. 
Electromyographic examination. Electromyographic examination of the triceps brachialis, 
tibialis, gastrocnemius and quadriceps femoris muscles was performed in mice anesthetized 
with isoflurane. Standard non-invasive needle electromyography was conducted on a Viking 
Quest EMG apparatus (Viasys, Nicolet Biomedical, Madison, Wisconsin) using concentric 
bipolar needle electrodes. Insertional activity and pathological spontaneous activity were rec-
orded. 
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Measurement of contractile properties. Absolute maximal isometric tetanic force (P0) was 
measured during tetanic contractions (frequency of 50-100 Hz, train of stimulation of 1,500 
ms for soleus and 750 ms for EDL). Specific maximal isometric force (sP0) was given as the 
quotient between force and muscle weight. For analysis of fatigue resistance, muscles were 
stimulated at 75 Hz for 500 ms, every 2 seconds over 3 minutes. See details in the Online 
Supplementary Material. 
Western blot. Protein was extracted from frozen tibialis anterior (TA) muscle of wild-type 
and mdx mice and processed as described50. Briefly, after homogenization of the muscle in 
RIPA buffer with a proteinase inhibitor cocktail (Complete®, Roche-Diagnostics) proteins 
were separated through denaturating SDS-PAGE with the Laemmli system and blotted onto 
nitrocellulose membranes by the semidry method (Biometra). The blots were probed with 
anti-porin as primary antibody (VDAC 31HL, AB-2, Calbiochem), anti-PGC1α (Santa-Cruz), 
anti-Nos1 (Abcam) and corresponding peroxidase-labeled secondary antibodies. The desmin 
and GAPDH bands were used as loading control for muscle. Bands were visualized by chemi-
luminescence. The protein bands were quantified by measuring their integrated density within 
a rectangle that covered the entire individual band and subtracting the integrated density of an 
empty rectangle of exactly the same size in the vicinity using the ImageJ software. 
Enzyme measurements. Enolase, citrate synthase [CS], cytochrome C oxidase [COX] and 
hydroxyacyl-CoA-dehydrogenase [HADHA] activities were determined in extracts from fro-
zen cryostat sections using a coupled enzyme assay as detailed in the Online Supplementary 
Material. 
Histology and SDS-PAGE. H&E, SDH and COX staining were performed using routine his-
tological protocols. The following primary antibodies were used for immunohistochemistry: 
anti-CD31 (Pharmingen), anti-MHCIIA (SC-71, DSMZ), anti-MHCI (BAD5, DSMZ), anti-
Nos1 (Abcam) and anti-laminin (Dako) followed by secondary antibodies with various fluo-
rophores (Alexa Fluor®, Invitrogen). See details in the Online Supplementary Material. 
Morphometric analysis of capillary number and capillary domains: Cryosections of 12 
µm of the EDL and soleus muscles of PBS- and sActRIIB-Fc treated animals were stained 
with anti-laminin to delineate the muscle fibers. Muscle capillaries were stained with anti-
CD31. Fluorescent photographs were taken with a 20x objective on a Microscope (Zeiss, 
AxioImager Z1) and saved as TIFF files. These images were projected on a flatscreen coupled 
with a graphic tablet, which enabled the manual retracing of the muscle fiber outlines and the 
counting of capillaries that were found around it. For the EDL, the fibers of the entire muscle 
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cross section were analyzed, and for the soleus muscle, the fibers from 10 representative non-
overlapping visual fields. For each muscle fiber we determined the cross sectional plane 
[µm2] and counted the number of bordering capillaries. The capillary domain [µm2] for each 
fiber was calculated by dividing its cross sectional plane by the number of bordering capilla-
ries. 
Cell Culture. C2C12 cells were grown in DMEM (Gibco 41966-029) supplemented with 1% 
Pen/Strep and 20% FBS (Gibco 10500-064) to semiconfluency at 37oC and 5% CO2 for 2 
days. Thereafter, the medium was replaced by DMEM + 10% horse serum (Gibco 26050-088) 
to induce fusion into multinucleated myotubes. sActRIIB-Fc was added to a final concentra-
tion of 200 ng/ml to the culture medium of the myotubes. After 24 h, the myotubes were har-
vested by trypsinization, washed and pelleted for RNA extraction. Human umbilical vein en-
dothelial cells (HUVEC) were grown to confluency, trypsinized and pelleted for RNA extrac-
tion. The doubling time of the cells was determined using the AlamarBlue reagents from Invi-
trogen (UK). Briefly, cells were plated at 20% confluency and allowed to settle for 12 h be-
fore introducing recombinant myostatin (R&D Systems). The cells were grown for 24 h be-
fore addition of 0.1 volume of AlamarBlue reagent and incubation at 37oC for 20 min before 
photometric analysis. The cells were then washed and cultured in fresh medium containing 
myostatin. Cell proliferation was monitored every 24 h for 4 days after initial introduction of 
myostatin. Cell number was determined by comparison of absorbance against a standard 
curve. All experiments were performed in triplicate. 
RT-qPCR. Real-Time qPCR was performed according the SYBR Green® protocol (Applied 
Biosystems) on the Eco Real-Time PCR System (Illumina) with a HotStart Taq polymerase. 
For primer sequences see Online Supplementary Material. Fold changes were calculated ac-
cording to the efficiency corrected -ΔΔCt method. The use of normal and of DMD muscle 
from patients was covered by the approval of the ethical review board of the Charité 
(#216/2001). All patients or their legal guardians provided written informed consent accord-
ing to the Declaration of Helsinki. 
In vivo MRS investigation of muscle function and oxidative metabolism. Mice were anes-
thetized with 4% isoflurane in 100% air at a flow of 3 l/min and were placed into a home-built 
cradle specifically designed for the strictly noninvasive MRS investigation of muscle function 
and energetics30. Throughout the experiment, anesthesia was maintained using a facemask 
continuously supplying 1.75% isoflurane in 33% O2 (0.2 l/min) and 66% N2O (0.4 l/min). 
Animal body temperature was controlled by a rectal probe and maintained at physiological 
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values by a feedback loop that regulated an electrical heating blanket. MR spectra were rec-
orded in the 4.7 T horizontal magnet of a 47/30 Biospec Avance MR system (Bruker, 
Karlsruhe, Germany) equipped with a Bruker 120-mm BGA12SL (200 mT/m) gradient insert. 
Calf muscle were electro-stimulated transcutaneously to produce maximal repeated isometric 
contractions at a frequency of 1.7 Hz. Mechanical performance was measured using a foot 
pedal coupled to a force transducer. Concentrations of phosphorylated compounds and intra-
cellular pH of the calf muscle were continuously measured with an elliptic (8 x 12 mm2) 31P-
MRS surface coil during 6 min of rest, 6 min of electro-stimulation and 16 min of recovery. 
MRS data were processed using a custom-written analysis program developed on the IDL 
software (Research System, Boulder, CO, USA). In order to determine the time constant of 
post-exercise phosphocreatine re-synthesis (τPCr, an in vivo index of oxidative mitochondrial 
capacity), the time course of phosphocreatine concentrations during the post-stimulation pe-
riod was fitted to a mono-exponential function with a least mean-squared algorithm (Fig. 5d): 
τPCr = -t/ln(PCrt/ΔPCr), where ΔPCr is the extent of PCr depletion measured at the start of 
recovery period. 
Statistical analysis. Data were analyzed and significance levels calculated using the non-
parametric Wilcoxon-Mann-Whitney U-Test, as stated in the legends and detailed in the On-
line Supplementary Material. Values are presented as means ± SEM (Standard Error of the 
Mean). Significance levels were set at p<0.05. 
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FIGURE LEGENDS 
Figure 1: Treatment of adult wild-type mice with sActRIIB-Fc. All tests were done after a 
4 months treatment of the wild-type mice with either sActRIIB-Fc or PBS (controls). (a) Ab-
solute maximal force (n=10 for each condition), and (b) specific maximal force of EDL and 
soleus muscles (n=10 for each condition). (c) Force recordings during the fatigue protocol 
over 180 s, and (d) Fatigue resistance of EDL (n=9 for PBS treated mice and n=8 for sAc-
tRIIB-Fc treated mice) and soleus muscles (n=10 for PBS treated mice and n=9 for sActRIIB-
Fc treated mice). (e) Running distances during incremental speed running until exhaustion 
(n=5 for each condition). (f) Serum lactate levels at rest and 5 min after incremental speed 
running until exhaustion (n=5 for each condition). (g) A plot depicting the relationship be-
tween travel distance until exhaustion during incremental speed running and serum lactate, 
which was measured 5 min after exhaustion, for individual mice (n=5 for each condition). (h) 
Critical Speed before and after 1, 2 and 4 months of treatment with sActRIIB-Fc in compari-
son to PBS-treated control mice (n=5 for each condition). (i) A plot depicts the proportional 
relationship between distance run (y-axis) and time to exhaustion (x-axis) at different veloci-
ties. The slope of the regression line indicates the Critical Speed. Values are shown as means 
± SEM. p-Values were calculated using the nonparametric U-Test. 
Figure 2: Treatment of adult mdx mice with sActRIIB-Fc. All tests were performed after a 
4 months treatment of the mdx mice with either sActRIIB-Fc or PBS (controls). (a) Absolute 
maximal force (n=9 for each condition for EDL muscles and n=10 for each condition for so-
leus muscles), and (b) specific maximal force of EDL (n=9 for each condition) and soleus 
muscles (n=10 for each condition). (c) Force recordings during the fatigue protocol over 180 s 
of EDL and soleus muscles, and (d) fatigue resistance for EDL (n=8 for each condition) and 
soleus (n=10 for PBS treated mice and n=8 for sActRIIB-Fc treated mice). (e) Running dis-
tance during incremental speed running until exhaustion (n=5 for each condition). (f) Serum 
lactate levels at rest and 5 min after incremental speed running until exhaustion (n=5 for each 
condition). (g) A plot depicts the relationship between travel distance until exhaustion during 
incremental speed running and serum lactate, which was measured 5 min after exhaustion, for 
individual mice (n=5 for each condition). (h) Critical Speed before and after 1, 2 and 4 
months of treatment with sActRIIB-Fc in comparison to PBS (n=5 for each condition). (i) A 
plot depicts the proportional relationship between distance run (y-axis) and time to exhaustion 
(x-axis) at different velocities. The slope of the regression line indicates the Critical Speed. 
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Values are shown as means ± SEM. p-Values were calculated using the nonparametric U-
Test. 
Figure 3: The effect of myostatin/ActRIIB signaling on vascularization. All investigations 
were done after a 4 months treatment of wild-type and mdx mice with either sActRIIB-Fc or 
PBS (controls). (a-d) Capillarization of wild-type soleus (n=430 fibers from PBS treated 
muscles (n=3) and n=300 fibers from sActRIIB-Fc treated muscles (n=3)) and mdx soleus 
muscle (n=605 fibers from PBS treated muscles (n=3) and n=836 fibers from sActRIIB-Fc 
treated muscles (n=4)). Histograms in (a) and (c) depict the distribution of capillaries per 
muscle fiber (in [%]), whereas diagrams in (b) and (d) depict the capillary domain, the fiber 
area per capillary (in [µm2]). Values are depicted as means ± SEM. (e) Vegf-A relative 
mRNA-copy numbers as expressed per 106 x 18S rRNA copies in wild-type TA muscle (n=5 
for each condition). (f) Vegf-A relative mRNA-copy numbers in C2C12 myotubes following 24 
h treatment with sActRIIB-Fc in comparison to control cultures (n=3 for each condition). (g) 
Relative mRNA-copy numbers of MSTN and myostatin receptors ActRIIA/B and ALK4/5 in 
cultures of human umbilical vein endothelial cells (HUVEC) in comparison to muscle sam-
ples from a healthy control and a patient with Duchenne muscular dystrophy. Values are 
shown as means ± SEM. p-Values were calculated using the nonparametric U-Test.  
Figure 4: Effect of myostatin/ActRIIB signaling on muscle metabolic phenotype. All in-
vestigations were done after a 4 months treatment of wild-type (n=5 for each condition) and 
mdx mice (n=5 for each condition) with either sActRIIB-Fc or PBS (controls). (a) Western 
blots (left side) depict bands for Pgc1α referenced to Desmin. The bar chart (right side) de-
picts the quotients of Pgc1α/Desmin band densities. (b) Pgc1α and (c) Pparβ relative copy 
numbers in the TA muscle from wild-type and mdx mice as expressed per 106 x 18S rRNA 
copies. (d) Enolase enzymatic activity in wildtype EDL (n=5 for each condition) and wildtype 
soleus muscles (n=5 for each condition). (e-f) Relative mRNA-copy numbers of genes in-
volved in the regulation of the oxidative metabolism in TA muscle from wild-type and mdx 
mice and (g) from C2C12 myotubes following 24 h treatment with sActRIIB-Fc in comparison 
to control cultures (n=3 for each condition). Values are shown as means ± SEM. p-Values 
were calculated using the nonparametric U-Test. 
Figure 5: In vivo investigation of muscle function and oxidative metabolism in mdx calf 
muscles by non-invasive 31P-MRS. Investigations were done in mdx mice that were treated 
either with sActRIIB-Fc (n=5) or with PBS (controls; n=4). (a) The extent of force reduction 
was measured at the end of the 6 min period of electro-stimulation and is represented as per-
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cent of the starting value. (b) The drop of intracellular pH and (c) phosphocreatine (PCr) con-
centration was determined at the end of the 6 min in vivo electro-stimulation period. (d) For 
each animal, the post-stimulation time course of PCr was fitted to a mono-exponential func-
tion with a least mean-squared algorithm in order to calculate the PCr recovery time constant 
(τPCr): τPCr = -t/ln(PCrt/ΔPCr). (e) τPCr was significantly larger in sActRIIB-Fc treated mdx 
mice (200 ± 39 s versus 78 ± 20 s in the control group). Values are shown as means ± SEM. 
p-Values were calculated using the nonparametric U-Test. 





